Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience

Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refractory chronic lymphocytic leukemia (CLL), even in cases with unfavorable cytogenetics and molecular markers. All CLL patients’ data treated at our Institute with ibrutinib have been retrospectively re...

Descripción completa

Detalles Bibliográficos
Autores principales: Broccoli, Alessandro, Argnani, Lisa, Morigi, Alice, Nanni, Laura, Casadei, Beatrice, Pellegrini, Cinzia, Stefoni, Vittorio, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706288/
https://www.ncbi.nlm.nih.gov/pubmed/34945141
http://dx.doi.org/10.3390/jcm10245845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706288/
https://www.ncbi.nlm.nih.gov/pubmed/34945141
http://dx.doi.org/10.3390/jcm10245845

Ejemplares similares